Effects of Goji vs. Fiber on Macular Degeneration

Last updated: May 8, 2024
Sponsor: University of California, Davis
Overall Status: Active - Recruiting

Phase

N/A

Condition

Macular Degeneration

Geographic Atrophy

Aging

Treatment

Goji berry

Fiber

Clinical Study ID

NCT06237127
2082960
  • Ages 50-95
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this project is to conduct a clinical trial in 60 participants ranging from age 50-95 with small drusen who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 28g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of small drusen by a retinal specialist
  • Willingness and ability to comply with the study protocol
  • 50 - 95 years of age

Exclusion

Exclusion Criteria:

  • Dislike of, or allergy to, goji berries or any of the ingredients in the fiber-richwafers and gummies (wheat, corn, oats, soy, natural orange flavor, xylitol, annatto,pectin, or other food ingredients)
  • Consumption of > 2 alcoholic drinks per day
  • Indications of substance or alcohol abuse
  • Current or planned use of a blood thinner (e.g., Coumadin, Warfarin) at any timeduring study
  • Use of multi-vitamin or any other supplements that contain lutein and/or zeaxanthin (if willing to stop the supplement, subject can be enrolled 6 months from stop date)
  • Taking any new medications started within the past 6 months, or changes in medicationregimen planned in the next 6 months (stable use greater than 6 months is notexclusionary)
  • Any planned international travel during the study
  • Consuming >3 servings/day of a combination of spinach, kale, lettuce, orange bellpeppers, corn, parsley, squash, broccoli, pumpkin, edamame
  • Regularly consuming >3 eggs/day
  • Currently participating in any other interventional research study
  • Diagnosed with inflammatory bowel disease, irritable bowel syndrome, othergastrointestinal disorder, undergoing cancer therapy or immunocompromised, ordiagnosis of another condition where lutein, zeaxanthin and/or fiber supplementationwould be contraindicated or would interfere with ability to participate in the study
  • Any physical characteristic or condition that precludes ability to perform studyprocedures
  • Medical or psychiatric condition that, in the opinion of the Investigator, wouldcompromise study findings or prevent the participant from completing the study

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Goji berry
Phase:
Study Start date:
April 29, 2024
Estimated Completion Date:
June 30, 2027

Study Description

Age-related macular degeneration (AMD) is the third leading cause of blindness worldwide. The disease occurs when the macula in the central retina develops lesions due, in part, to the loss of the protection of macular pigments zeaxanthin, lutein, and meso-zeaxanthin, which are responsible for light filtering and oxidative defense. The major risk factor for AMD is aging, and currently, no definitive prevention for AMD exists.

Goji berry (Lycium Barbarum) is a fruit that has been used as traditional medicine in Asian countries for more than 2,000 years. Modern science has identified potential benefits of the berry in oxidant defense, immune regulation, diabetes, and vision in animal and cell models. Nonetheless, evidence regarding the effects of goji berries on human health is scarce. The bioactive components of goji berries include zeaxanthin, lutein, Lycium Barbarum polysaccharides-protein complex, betaine, cerebroside, minerals, and vitamins. Importantly, goji berries contain the highest concentration of zeaxanthin among all commonly consumed foods.

Previous clinical studies have shown that goji berries have a high bioavailability of zeaxanthin, and that macular pigment optical density (MPOD) was increased after supplementation. This study uses macular pigment optical volume (MPOV; a measure that integrates MPOD across multiple macular eccentricities) as the primary outcome measure. It is unknown if the changes in MPOV will be associated with other functional changes or anatomic conditions in the eye among a population with small drusen, a risk factor for AMD. In addition, the impact of goji berry intake on the gut microbiome profile and associated metabolites is unknown, and potentially important in understanding the mechanism(s) of action.

Participants who meet the eligibility criteria will be enrolled and will be randomized 1:1 to the goji berry arm or fiber arm of the study. Over the course of approximately 180 days, participants will consume the assigned food item five days per week and attend three study visits.

Study visits will include ophthalmic imaging and testing, skin carotenoid measurements, completion of a food record, height, weight, handgrip strength, blood pressure measurement, and fasting blood collection. At 2 timepoints participants will be asked to provide a stool sample (collected within 24 hours of visit).

Connect with a study center

  • UC Davis Eye Center, Tschannen Eye Institute

    Sacramento, California 95817
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.